NASDAQ:CNMD - CONMED Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$68.38 -0.04 (-0.06 %)
(As of 05/27/2018 05:49 AM ET)
Previous Close$68.38
Today's Range$68.02 - $68.98
52-Week Range$47.41 - $69.55
Volume63,840 shs
Average Volume160,052 shs
Market Capitalization$1.92 billion
P/E Ratio33.36
Dividend Yield1.17%
Beta0.6

About CONMED (NASDAQ:CNMD)

CONMED logoCONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company's products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:CNMD
CUSIP20741010
Phone315-797-8375

Debt

Debt-to-Equity Ratio0.69
Current Ratio2.15
Quick Ratio1.23

Price-To-Earnings

Trailing P/E Ratio33.36
Forward P/E Ratio31.51
P/E Growth2.74

Sales & Book Value

Annual Sales$796.39 million
Price / Sales2.41
Cash Flow$4.0035 per share
Price / Cash17.08
Book Value$22.92 per share
Price / Book2.98

Profitability

EPS (Most Recent Fiscal Year)$1.89
Net Income$55.48 million
Net Margins8.71%
Return on Equity9.46%
Return on Assets4.28%

Miscellaneous

Employees3,100
Outstanding Shares28,040,000

CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Thursday, May 24th. Stockholders of record on Friday, June 15th will be given a dividend of $0.20 per share on Thursday, July 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend is Thursday, June 14th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) issued its quarterly earnings data on Wednesday, April, 25th. The medical technology company reported $0.53 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.10. The medical technology company had revenue of $202.10 million for the quarter, compared to analyst estimates of $196.51 million. CONMED had a return on equity of 9.46% and a net margin of 8.71%. CONMED's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.38 EPS. View CONMED's Earnings History.

When is CONMED's next earnings date?

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $2.15-$2.20 for the period, compared to the Thomson Reuters consensus estimate of $2.14.

What price target have analysts set for CNMD?

3 analysts have issued 1 year price objectives for CONMED's stock. Their forecasts range from $46.00 to $73.00. On average, they expect CONMED's stock price to reach $59.50 in the next year. View Analyst Ratings for CONMED.

What are Wall Street analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:
  • 1. According to Zacks Investment Research, "CONMED exited the first quarter of 2018 with strong top-line growth and margin expansion. Strong performances by Advanced Surgical and Endoscopic Technologies buoy optimism. We are also upbeat about the continued innovation undertaken by the company over the last year. Solid revenue guidance is indicative of brighter prospects. CONMED is also benefiting from the increasing trend of using minimally invasive techniques as a large percentage of the company’s products are designed for these procedures. CONMED outperformed the industry in a year’s time. CONMED operates in a highly competitive environment, especially in the General Surgery business. Lower healthcare spending buoyed by the foreign exchange volatility is a headwind. Moreover, CONMED’s stock looks much overvalued at the moment. Pricing pressures add to the woes. Long-term debt at the end of the just-reported first quarter was also high, raising concerns." (4/27/2018)
  • 2. Needham & Company LLC analysts commented, "We hosted investor meetings in Boston with CNMD’s CEO and CFO earlier this week. We believe that CNMD is making progress in its turnaround, as evidenced by its organic revenue growth of 3% year-to-date (YTD), which is a considerable improvement from the bottom of (3%) growth in 2H14. We expect further improvement in its domestic Orthopedic Surgery business as new products continue to gain momentum and believe that this can push overall revenue growth towards 5%. We also believe that margin expansion will be the next chapter in the CNMD story given higher revenue growth, a reduced currency headwind, and a renewed focus on cost reductions. CNMD’s operating margin is currently around 9% and we see potential for this to reach the mid-teens or higher over time. We think the stock looks undervalued at a P/E of 25.5x our 2018E estimate considering that we think its potential earnings power is $3.00+ per share and we reiterate our Buy rating." (11/17/2017)

Who are some of CONMED's key competitors?

Who are CONMED's key executives?

CONMED's management team includes the folowing people:
  • Mr. Curt R. Hartman, CEO, Pres & Director (Age 54)
  • Mr. Patrick J. Beyer, Pres of CONMED International (Age 52)
  • Mr. Luke A. Pomilio, Advisor to Chief Financial Officer (Age 53)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 43)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 43)

Has CONMED been receiving favorable news coverage?

Media stories about CNMD stock have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CONMED earned a news impact score of 0.14 on Accern's scale. They also assigned news articles about the medical technology company an impact score of 45.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are CONMED's major shareholders?

CONMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.69%), Scopia Capital Management LP (7.75%), Dimensional Fund Advisors LP (7.40%), Victory Capital Management Inc. (6.46%), Champlain Investment Partners LLC (4.72%) and Northern Trust Corp (2.22%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert and Terence M Berge. View Institutional Ownership Trends for CONMED.

Which major investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Victory Capital Management Inc., Champlain Investment Partners LLC, Dimensional Fund Advisors LP, Thrivent Financial for Lutherans, Westwood Holdings Group Inc., Citadel Advisors LLC and Lord Abbett & CO. LLC. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, Jo Ann Golden, Luke A Pomilio, Nathan Folkert and Terence M Berge. View Insider Buying and Selling for CONMED.

Which major investors are buying CONMED stock?

CNMD stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., WINTON GROUP Ltd, Prudential Financial Inc., Hsbc Holdings PLC, Prescott Group Capital Management L.L.C., Epoch Investment Partners Inc., Summit Global Investments and A.R.T. Advisors LLC. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $68.38.

How big of a company is CONMED?

CONMED has a market capitalization of $1.92 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.


MarketBeat Community Rating for CONMED (CNMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  452
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CONMED (NASDAQ:CNMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for CONMED in the last 12 months. Their average twelve-month price target is $59.50, suggesting that the stock has a possible downside of 12.99%. The high price target for CNMD is $73.00 and the low price target for CNMD is $46.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.252.252.25
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $59.50$55.6667$55.00$50.6667
Price Target Upside: 12.99% downside11.79% downside4.81% downside2.41% downside

CONMED (NASDAQ:CNMD) Consensus Price Target History

Price Target History for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$71.00 ➝ $73.00HighView Rating Details
11/3/2017KeyCorpReiterated RatingHoldN/AView Rating Details
11/3/2017Piper Jaffray CompaniesReiterated RatingHold$46.00N/AView Rating Details
4/27/2017Ladenburg ThalmannDowngradeBuy ➝ Neutral$50.00 ➝ $48.00HighView Rating Details
11/23/2016Leerink SwannReiterated RatingHold ➝ NeutralN/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

CONMED (NASDAQ:CNMD) Earnings History and Estimates Chart

Earnings by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Earnings Estimates

2018 EPS Consensus Estimate: $2.07
2019 EPS Consensus Estimate: $2.42
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.42$0.43$0.43
Q2 20183$0.45$0.46$0.45
Q3 20183$0.41$0.48$0.45
Q4 20183$0.72$0.78$0.74
Q1 20191$0.49$0.49$0.49
Q2 20191$0.54$0.54$0.54
Q3 20191$0.55$0.55$0.55
Q4 20191$0.84$0.84$0.84

CONMED (NASDAQ CNMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2018$0.45N/AView Earnings Details
4/25/2018Q1 2018$0.43$0.53$196.51 million$202.10 millionViewN/AView Earnings Details
1/31/2018Q4 2017$0.65$0.69$212.17 million$222.60 millionViewN/AView Earnings Details
11/2/2017Q3 2017$0.41$0.42$187.13 million$190.10 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.41$0.41$194.50 million$197.20 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.35$0.38$181.47 million$186.57 millionViewN/AView Earnings Details
2/1/2017Q416$0.56$0.54$204.04 million$204.10 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.41$180.13 million$184.79 millionViewListenView Earnings Details
7/27/2016Q216$0.46$0.47$191.48 million$193.40 millionViewListenView Earnings Details
4/27/2016Q116$0.41$0.42$180.15 million$181.20 millionViewListenView Earnings Details
1/27/2016Q415$0.51$0.52$191.03 million$191.00 millionViewListenView Earnings Details
10/21/2015Q315$0.44$0.38$173.96 million$169.20 millionViewListenView Earnings Details
7/21/2015Q215$0.44$0.36$182.40 million$181.00 millionViewListenView Earnings Details
4/22/2015Q115$0.41$0.42$176.16 million$177.90 millionViewListenView Earnings Details
1/27/2015Q414$0.54$0.53$196.00 million$195.00 millionViewListenView Earnings Details
10/23/2014Q314$0.39$0.44$173.30 million$175.00 millionViewListenView Earnings Details
7/23/2014Q214$0.47$0.47$190.62 million$188.20 millionViewListenView Earnings Details
4/24/2014Q1$0.47$0.49$191.95 million$181.90 millionViewListenView Earnings Details
2/13/2014Q413$0.49$0.53$197.24 million$203.40 millionViewListenView Earnings Details
10/24/2013Q313$0.40$0.40$186.20 million$179.30 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.44$0.43$193.55 million$193.00 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.45$0.45$196.79 million$187.00 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.50$0.52$200.12 million$201.20 millionViewListenView Earnings Details
10/25/2012$0.40$0.43ViewN/AView Earnings Details
7/26/2012$0.45$0.43ViewN/AView Earnings Details
4/26/2012$0.44$0.43ViewN/AView Earnings Details
2/15/2012$0.39$0.46ViewN/AView Earnings Details
10/27/2011$0.31$0.33ViewN/AView Earnings Details
7/28/2011$0.35$0.35ViewN/AView Earnings Details
4/28/2011$0.31$0.37ViewN/AView Earnings Details
2/3/2011$0.36$0.36ViewN/AView Earnings Details
10/28/2010Q3 2010$0.28$0.34ViewN/AView Earnings Details
7/29/2010Q2 2010$0.26$0.32ViewN/AView Earnings Details
4/29/2010Q1 2010$0.26$0.28ViewN/AView Earnings Details
2/4/2010Q4 2009$0.32$0.37ViewN/AView Earnings Details
10/22/2009Q3 2009$0.17$0.28ViewN/AView Earnings Details
7/30/2009Q2 2009$0.16$0.17ViewN/AView Earnings Details
4/23/2009Q1 2009$0.24$0.19ViewN/AView Earnings Details
2/5/2009Q4 2008$0.30$0.34ViewN/AView Earnings Details
10/23/2008Q3 2008$0.34$0.37ViewN/AView Earnings Details
7/24/2008Q2 2008$0.39$0.43ViewN/AView Earnings Details
4/24/2008Q1 2008$0.35$0.38ViewN/AView Earnings Details
2/7/2008Q4 2007$0.38$0.44ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CONMED (NASDAQ:CNMD) Dividend Information

CONMED pays an annual dividend of $0.80 per share, with a dividend yield of 1.17%. CNMD's next quarterly dividend payment will be made on Thursday, July 5. CONMED pays out 42.33% of its earnings out as a dividend.
Next Dividend:7/5/2018
Annual Dividend:$0.80
Dividend Yield:1.17%
Payout Ratio(s):42.33% (Trailing 12 Months of Earnings)
36.87% (Based on This Year's Estimates)
33.20% (Based on Next Year's Estimates)
19.98% (Based on Cash Flow)
Dividend Payments by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/24/2018quarterly$0.201.17%6/14/20186/15/20187/5/2018
2/28/2018quarterly$0.201.31169044105591%3/14/20183/15/20184/5/2018
11/28/2017quarterly$0.201.48%12/14/201712/15/20171/5/2018
8/29/2017quarterly$0.201.65%9/14/20179/15/201710/5/2017
5/24/2017quarterly$0.201.6%6/13/20176/15/20177/5/2017
2/28/2017quarterly$0.201.92%3/13/20173/15/20174/5/2017
11/21/2016quarterly$0.201.77%12/13/201612/15/20161/5/2017
8/25/2016quarterly$0.201.99%9/13/20169/15/201610/5/2016
5/25/2016quarterly$0.202.05%6/13/20166/15/20167/6/2016
2/23/2016quarterly$0.202.1%3/11/20163/15/20164/5/2016
11/16/2015quarterly$0.201.92%12/11/201512/15/20151/5/2016
8/24/2015quarterly$0.201.53%9/11/20159/15/201510/5/2015
5/29/2015quarterly$0.201.44%6/11/20156/15/20157/6/2015
2/25/2015quarterly$0.201.56%3/12/20153/16/20154/6/2015
11/18/2014quarterly$0.201.92%12/11/201412/15/20141/5/2015
8/25/2014quarterly$0.202.11%9/11/20149/15/201410/6/2014
5/23/2014quarterly$0.201.8%6/12/20146/16/20147/7/2014
2/27/2014quarterly$0.201.72%3/13/20143/17/20144/7/2014
10/28/2013quarterly$0.2012/12/201312/16/20131/6/2014
8/27/2013quarterly$0.151.91%9/12/20139/16/201310/4/2013
5/24/2013quarterly$0.151.76%6/13/20136/17/20137/8/2013
2/27/2013quarterly$0.151.93%3/13/20133/15/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

CONMED (NASDAQ CNMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.13%
Institutional Ownership Percentage: 95.19%
Insider Trading History for CONMED (NASDAQ:CNMD)
Institutional Ownership by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ CNMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018Jo Ann GoldenDirectorSell3,000$67.62$202,860.007,782View SEC Filing  
5/7/2018Jo Ann GoldenDirectorSell3,000$67.23$201,690.0010,782View SEC Filing  
4/27/2018Daniel JonasEVPSell2,000$65.58$131,160.0023,245View SEC Filing  
4/27/2018Jo Ann GoldenDirectorSell5,698$65.40$372,649.2019,480View SEC Filing  
4/27/2018Nathan FolkertVPSell4,409$64.98$286,496.821,264View SEC Filing  
3/9/2018Terence M BergeVPSell3,868$62.45$241,556.6019,908View SEC Filing  
3/1/2018Luke A PomilioCFOSell19,620$60.19$1,180,927.80600View SEC Filing  
2/12/2018Luke A. PomilioCFOSell1,962$60.25$118,210.50View SEC Filing  
2/1/2018Jo Ann GoldenDirectorSell3,000$63.90$191,700.00View SEC Filing  
2/1/2018Luke A. PomilioCFOSell18,023$63.38$1,142,297.74View SEC Filing  
1/3/2018Charles FarkasDirectorBuy158$50.61$7,996.3811,707View SEC Filing  
11/9/2017Luke A PomilioEVPSell29,363$50.70$1,488,704.1045,486View SEC Filing  
11/7/2017Luke A PomilioCFOSell12,429$50.63$629,280.2745,486View SEC Filing  
11/3/2017Luke A PomilioEVPSell10,020$53.57$536,771.4044,472View SEC Filing  
10/3/2017Charles FarkasDirectorBuy148$53.96$7,986.0811,549View SEC Filing  
8/14/2017Jo Ann GoldenDirectorSell3,000$50.00$150,000.0019,782View SEC Filing  
7/5/2017Charles FarkasDirectorBuy157$50.78$7,972.4611,401View SEC Filing  
6/13/2017Dirk KuyperDirectorSell1,000$52.24$52,240.0010,739View SEC Filing  
5/15/2017Daniel JonasEVPSell3,000$51.22$153,660.0014,455View SEC Filing  
4/3/2017Charles FarkasDirectorBuy180$44.41$7,993.808,505View SEC Filing  
3/13/2017Heather L CohenEVPBuy440$40.00$17,600.0011,291View SEC Filing  
3/10/2017Curt R HartmanCEOBuy8,030$40.11$322,083.3036,470View SEC Filing  
3/6/2017Mark E TryniskiDirectorBuy5,000$41.15$205,750.0027,000View SEC Filing  
1/3/2017Charles FarkasDirectorBuy305$44.65$13,618.258,325View SEC Filing  
11/8/2016Daniel JonasEVPSell1,500$41.78$62,670.0016,590View SEC Filing  
11/7/2016Daniel JonasEVPSell2,555$40.40$103,222.0020,120View SEC Filing  
10/3/2016Charles FarkasDirectorBuy336$40.04$13,453.448,020View SEC Filing  
7/1/2016Charles FarkasDirectorBuy282$47.87$13,499.347,684View SEC Filing  
6/3/2016Luke A PomilioCFOSell4,400$41.56$182,864.0041,884View SEC Filing  
4/1/2016Charles FarkasDirectorBuy338$42.04$14,209.524,399View SEC Filing  
3/4/2016Mark D SnyderEVPSell2,940$41.32$121,480.8014,262View SEC Filing  
3/2/2016John L WorkmanDirectorBuy2,500$39.85$99,625.004,500View SEC Filing  
2/19/2016Jerome J LandeDirectorSell1,630,800$38.28$62,427,024.004,000View SEC Filing  
1/4/2016Charles FarkasDirectorBuy332$42.18$14,003.764,064View SEC Filing  
12/11/2015David M BronsonDirectorBuy1,500$41.01$61,515.001,500View SEC Filing  
6/12/2015Jo Ann GoldenDirectorSell1,000$56.03$56,030.00View SEC Filing  
5/29/2015Stephen MandiaDirectorSell14,000$55.62$778,680.00View SEC Filing  
5/6/2015Pat BeyerInsiderBuy5,000$53.36$266,800.00View SEC Filing  
4/30/2015Stephen MandiaDirectorSell3,899$49.97$194,833.03View SEC Filing  
12/12/2014Stephen MandiaDirectorSell4,500$43.23$194,535.00View SEC Filing  
12/1/2014Dirk KuyperDirectorSell1,000$42.85$42,850.00View SEC Filing  
11/19/2014Joseph G DarlingEVPSell4,270$42.00$179,340.00View SEC Filing  
10/29/2014Robert D Shallish JrCFOSell10,410$41.67$433,784.70View SEC Filing  
9/4/2014William AbrahamEVPSell16,062$39.91$641,034.42View SEC Filing  
8/26/2014William AbrahamEVPSell7,423$38.36$284,746.28View SEC Filing  
8/21/2014William AbrahamEVPSell15,986$37.71$602,832.06View SEC Filing  
8/19/2014William AbrahamEVPSell5,312$37.75$200,528.00View SEC Filing  
7/31/2014Curt R HartmanCEOBuy10,000$39.25$392,500.00View SEC Filing  
7/30/2014Bruce DanielsDirectorSell1,600$39.31$62,896.00View SEC Filing  
7/30/2014Joseph J CorasantiCEOSell109,035$39.25$4,279,623.75View SEC Filing  
10/29/2013Joseph J CorasantiCEOSell80,148$36.47$2,922,997.56View SEC Filing  
10/28/2013Bruce DanielsDirectorSell4,500$36.43$163,935.00View SEC Filing  
9/13/2013Joseph CorasantiCEOSell44,852$33.04$1,481,910.08114,148View SEC Filing  
9/11/2013William AbrahamSVPSell7,423$33.48$248,522.0421,659View SEC Filing  
8/15/2013Dirk KuyperDirectorBuy1,000$31.63$31,630.001,000View SEC Filing  
6/7/2013Daniel JonasVPSell2,000$32.42$64,840.00View SEC Filing  
6/4/2013Heather L CohenVPSell1,200$32.59$39,108.00View SEC Filing  
5/31/2013Luke A PomilioVPSell2,556$33.19$84,833.64View SEC Filing  
5/29/2013Heather L CohenVPSell4,514$34.31$154,875.34View SEC Filing  
5/28/2013Robert D Shallish JrCFOSell10,000$34.35$343,500.00View SEC Filing  
2/15/2013Stuart J SchwartzDirectorSell1,000$30.32$30,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CONMED (NASDAQ CNMD) News Headlines

Source:
DateHeadline
CONMED (CNMD) Up 9.1% Since Earnings Report: Can It Continue?CONMED (CNMD) Up 9.1% Since Earnings Report: Can It Continue?
finance.yahoo.com - May 25 at 4:18 PM
CONMED Co. Plans Quarterly Dividend of $0.20 (CNMD)CONMED Co. Plans Quarterly Dividend of $0.20 (CNMD)
www.americanbankingnews.com - May 24 at 4:43 PM
CONMED Co. (CNMD) Expected to Post Quarterly Sales of $207.13 MillionCONMED Co. (CNMD) Expected to Post Quarterly Sales of $207.13 Million
www.americanbankingnews.com - May 22 at 2:34 AM
Zacks: Analysts Expect CONMED Co. (CNMD) to Announce $0.45 Earnings Per ShareZacks: Analysts Expect CONMED Co. (CNMD) to Announce $0.45 Earnings Per Share
www.americanbankingnews.com - May 20 at 5:14 PM
Global Surgical Stapling Devices Market Growth Opportunities: Conmed Corporation, Medtronic IncGlobal Surgical Stapling Devices Market Growth Opportunities: Conmed Corporation, Medtronic Inc
www.marketwatch.com - May 16 at 10:04 AM
CONMED Co. (CNMD) Director Sells $202,860.00 in StockCONMED Co. (CNMD) Director Sells $202,860.00 in Stock
www.americanbankingnews.com - May 11 at 1:22 PM
CONMED Co. (CNMD) Director Sells $201,690.00 in StockCONMED Co. (CNMD) Director Sells $201,690.00 in Stock
www.americanbankingnews.com - May 8 at 1:17 PM
CONMED Co. (CNMD) Given Average Rating of "Buy" by AnalystsCONMED Co. (CNMD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 7 at 9:05 AM
 Brokerages Expect CONMED Co. (CNMD) Will Post Quarterly Sales of $207.13 Million Brokerages Expect CONMED Co. (CNMD) Will Post Quarterly Sales of $207.13 Million
www.americanbankingnews.com - May 5 at 4:21 AM
CONMED (CNMD) Upgraded to "Strong-Buy" at BidaskClubCONMED (CNMD) Upgraded to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - May 5 at 12:29 AM
$0.45 Earnings Per Share Expected for CONMED Co. (CNMD) This Quarter$0.45 Earnings Per Share Expected for CONMED Co. (CNMD) This Quarter
www.americanbankingnews.com - May 3 at 10:17 AM
Analyzing CONMED (CNMD) & Edap Tms (EDAP)Analyzing CONMED (CNMD) & Edap Tms (EDAP)
www.americanbankingnews.com - May 2 at 5:44 PM
Daniel Jonas Sells 2,000 Shares of CONMED Co. (CNMD) StockDaniel Jonas Sells 2,000 Shares of CONMED Co. (CNMD) Stock
www.americanbankingnews.com - April 30 at 4:14 PM
CONMED Co. (CNMD) VP Nathan Folkert Sells 4,409 SharesCONMED Co. (CNMD) VP Nathan Folkert Sells 4,409 Shares
www.americanbankingnews.com - April 30 at 4:14 PM
CONMED Co. (CNMD) Director Jo Ann Golden Sells 5,698 SharesCONMED Co. (CNMD) Director Jo Ann Golden Sells 5,698 Shares
www.americanbankingnews.com - April 30 at 4:14 PM
CONMED Co. to Post Q4 2018 Earnings of $0.72 Per Share, Leerink Swann Forecasts (CNMD)CONMED Co. to Post Q4 2018 Earnings of $0.72 Per Share, Leerink Swann Forecasts (CNMD)
www.americanbankingnews.com - April 30 at 4:18 AM
CONMED (CNMD) Lifted to Hold at Zacks Investment ResearchCONMED (CNMD) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 27 at 12:44 PM
FY2018 Earnings Estimate for CONMED Co. (CNMD) Issued By Leerink SwannFY2018 Earnings Estimate for CONMED Co. (CNMD) Issued By Leerink Swann
www.americanbankingnews.com - April 27 at 9:34 AM
KeyCorp Research Analysts Lower Earnings Estimates for CONMED Co. (CNMD)KeyCorp Research Analysts Lower Earnings Estimates for CONMED Co. (CNMD)
www.americanbankingnews.com - April 27 at 7:58 AM
Piper Jaffray Comments on CONMED Co.s Q2 2018 Earnings (CNMD)Piper Jaffray Comments on CONMED Co.'s Q2 2018 Earnings (CNMD)
www.americanbankingnews.com - April 27 at 7:58 AM
CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 GuidanceCONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance
finance.yahoo.com - April 26 at 4:12 PM
Edited Transcript of CNMD earnings conference call or presentation 25-Apr-18 8:30pm GMTEdited Transcript of CNMD earnings conference call or presentation 25-Apr-18 8:30pm GMT
finance.yahoo.com - April 26 at 4:12 PM
Needham & Company LLC Boosts CONMED (CNMD) Price Target to $73.00Needham & Company LLC Boosts CONMED (CNMD) Price Target to $73.00
www.americanbankingnews.com - April 26 at 11:24 AM
BRIEF-Conmed Corporation Q1 GAAP Earnings Per Share $0.37BRIEF-Conmed Corporation Q1 GAAP Earnings Per Share $0.37
www.reuters.com - April 26 at 9:35 AM
Conmed Raises FY18 Financial Guidance - Quick FactsConmed Raises FY18 Financial Guidance - Quick Facts
www.nasdaq.com - April 26 at 9:35 AM
CONMED (CNMD) Q1 2018 Results - Earnings Call TranscriptCONMED (CNMD) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 9:35 AM
CONMED (CNMD) Releases  Earnings Results, Beats Expectations By $0.10 EPSCONMED (CNMD) Releases Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - April 25 at 7:46 PM
CONMED (CNMD) Releases FY18 Earnings GuidanceCONMED (CNMD) Releases FY18 Earnings Guidance
www.americanbankingnews.com - April 25 at 6:28 PM
Conmed: 1Q Earnings SnapshotConmed: 1Q Earnings Snapshot
www.cnbc.com - April 25 at 4:21 PM
CONMED Corporation Announces First Quarter 2018 Financial ResultsCONMED Corporation Announces First Quarter 2018 Financial Results
finance.yahoo.com - April 25 at 4:21 PM
Is CONMED Corporation’s (NASDAQ:CNMD) PE Ratio A Signal To Buy For Investors?Is CONMED Corporation’s (NASDAQ:CNMD) PE Ratio A Signal To Buy For Investors?
finance.yahoo.com - April 25 at 10:00 AM
CONMED Co. (CNMD) Expected to Announce Quarterly Sales of $196.87 MillionCONMED Co. (CNMD) Expected to Announce Quarterly Sales of $196.87 Million
www.americanbankingnews.com - April 18 at 4:31 AM
CONMED (CNMD) Scheduled to Post Earnings on WednesdayCONMED (CNMD) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 18 at 2:30 AM
CONMED (CNMD) Rating Lowered to Hold at Zacks Investment ResearchCONMED (CNMD) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:47 PM
 Brokerages Expect CONMED Co. (CNMD) to Announce $0.43 EPS Brokerages Expect CONMED Co. (CNMD) to Announce $0.43 EPS
www.americanbankingnews.com - April 16 at 5:19 AM
Needham & Company LLC Boosts CONMED (CNMD) Price Target to $57.00Needham & Company LLC Boosts CONMED (CNMD) Price Target to $57.00
www.americanbankingnews.com - April 15 at 5:06 PM
CONMED (CNMD) Downgraded by BidaskClubCONMED (CNMD) Downgraded by BidaskClub
www.americanbankingnews.com - April 15 at 1:49 PM
CONMED Co. (CNMD) Given Consensus Recommendation of "Buy" by BrokeragesCONMED Co. (CNMD) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 8:49 AM
CONMED (CNMD) Upgraded to "Buy" at Zacks Investment ResearchCONMED (CNMD) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 1:49 PM
BidaskClub Upgrades CONMED (CNMD) to SellBidaskClub Upgrades CONMED (CNMD) to Sell
www.americanbankingnews.com - April 10 at 3:55 PM
CONMED Corporation to Present at Two Investor Conferences in MayCONMED Corporation to Present at Two Investor Conferences in May
finance.yahoo.com - April 5 at 4:10 PM
CONMED (CNMD) Stock Rating Lowered by BidaskClubCONMED (CNMD) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 4 at 12:57 PM
Global Surgical Stapling Devices Market Opportunities 2018: Conmed Corporation, Johnson & Johnson, Stryker CorporationGlobal Surgical Stapling Devices Market Opportunities 2018: Conmed Corporation, Johnson & Johnson, Stryker Corporation
www.marketwatch.com - April 3 at 10:10 AM
$196.87 Million in Sales Expected for CONMED Co. (CNMD) This Quarter$196.87 Million in Sales Expected for CONMED Co. (CNMD) This Quarter
www.americanbankingnews.com - April 1 at 4:38 AM
CONMED (CNMD) Stock Rating Upgraded by Zacks Investment ResearchCONMED (CNMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM
 Analysts Expect CONMED Co. (CNMD) Will Post Earnings of $0.43 Per Share Analysts Expect CONMED Co. (CNMD) Will Post Earnings of $0.43 Per Share
www.americanbankingnews.com - March 30 at 9:35 AM
CONMED (CNMD) Upgraded to Sell at BidaskClubCONMED (CNMD) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - March 30 at 9:27 AM
FY2018 Earnings Estimate for CONMED Co. (CNMD) Issued By GabelliFY2018 Earnings Estimate for CONMED Co. (CNMD) Issued By Gabelli
www.americanbankingnews.com - March 30 at 7:05 AM
BidaskClub Upgrades CONMED (CNMD) to Strong-BuyBidaskClub Upgrades CONMED (CNMD) to Strong-Buy
www.americanbankingnews.com - March 27 at 5:10 PM
CONMED (CNMD) Price Target Increased to $71.00 by Analysts at Needham & Company LLCCONMED (CNMD) Price Target Increased to $71.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - March 25 at 10:22 PM

SEC Filings

CONMED (NASDAQ:CNMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CONMED (NASDAQ:CNMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CONMED (NASDAQ CNMD) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.